Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ru-Fang Yeh

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Science Signaling|August 27, 2011
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Signaling|June 16, 2011
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsSaoirse O Dolly, Andrew J Wagner, Johanna C Bendell, et al.
Blood|August 14, 2010
Effect of FCGR2A and FCGR3A variants on CLL outcomeDavid Dornan, Olivia Spleiss, Ru-Fang Yeh, et al.
Nature Communications|February 10, 2011
Chromatin remodelling complex dosage modulates transcription factor function in heart developmentJun K Takeuchi, Xin Lou, Jeffrey M Alexander, et al.
Blood|March 26, 2013
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patientsAnnika Dufour, Giuseppe Palermo, Evelyn Zellmeier, et al.
Nature Genetics|July 7, 2009
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibilityMargaret Wrensch, Robert B Jenkins, Jeffrey S Chang, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2013
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapiesMatthew J Brauer, Guanglei Zhuang, Maike Schmidt, et al.
Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Science Signaling|August 27, 2011
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Science Signaling|June 16, 2011
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancerSusanna Stinson, Mark R Lackner, Alex T Adai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsSaoirse O Dolly, Andrew J Wagner, Johanna C Bendell, et al.
Blood|August 14, 2010
Effect of FCGR2A and FCGR3A variants on CLL outcomeDavid Dornan, Olivia Spleiss, Ru-Fang Yeh, et al.
Nature Communications|February 10, 2011
Chromatin remodelling complex dosage modulates transcription factor function in heart developmentJun K Takeuchi, Xin Lou, Jeffrey M Alexander, et al.
Blood|March 26, 2013
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patientsAnnika Dufour, Giuseppe Palermo, Evelyn Zellmeier, et al.
Nature Genetics|July 7, 2009
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibilityMargaret Wrensch, Robert B Jenkins, Jeffrey S Chang, et al.
Blood|June 12, 2014
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemiaMartin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2013
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapiesMatthew J Brauer, Guanglei Zhuang, Maike Schmidt, et al.
Nature Communications|September 14, 2021
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemiaJohannes Bloehdorn, Andrejs Braun, Amaro Taylor-Weiner, et al.
Pageof 4